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Editors: Anton N. Sidawy and Bruce A. PerlerEconomic analysis of endovascular repair versus
surveillance for patients with small abdominal aortic
aneurysms
Eric L. Eisenstein, Linda Davidson-Ray, Rex Edwards, Kevin J.
Anstrom, Kenneth Ouriel
Background: The Positive Impact of EndoVascular Options
for Treating Aneurysms Early (PIVOTAL) trial enrolled in-
dividuals with small (4.0- to 5.0-cm diameter) abdominal
aortic aneurysms (AAA) and reported no difference in rup-
ture or aneurysm-related death for patients who received
early endovascular repair (EVAR) vs surveillance with serial
imaging studies. We evaluated resource use, medical cost,
and quality of life outcomes associated with the PIVOTAL
treatment strategies.
Methods: This prospective economic and quality of life
study was conducted within a randomized trial, with PIV-
OTAL sites participating in the quality of life (n ¼ 67) and
economic (n ¼ 63) studies. The PIVOTAL trial randomized
728 patients (366 early EVAR and 362 surveillance). We
used information from 701 quality of life (351 early EVAR
and 350 surveillance) and 614 economic (314 early EVAR
and 300 surveillance) study participants enrolled in the
PIVOTAL trial. The main outcome measures were total
medical costs and the aneurysm repair rate at 48 months.
Results: After 6 months, the rate of aneurysm repair was 96
vs 10 per 100 patients in the early EVAR and surveillance
groups, respectively (difference, 86; 95% conﬁdence interval
[CI], 82-90; P < .0001), and total medical costs were greater
in the early EVAR group ($33,471 vs $5520; difference,
$27,951; 95% CI, $25,156-$30,746; P < .0001). In months 7
through 48, however, the rate of aneurysm repair was 54
per 100 patients in the surveillance group, and total medical
costs were higher for patients in the surveillance vs the
early EVAR group ($40,592 vs $15,197; difference, $25,394;
95% CI, $15,184-$35,605; P < .0001). At 48 months’ follow-
up, early EVAR patients had greater cumulative use of AAA
repair (97 vs 64 per 100 patients; difference, 34; 95% CI, 21-
46; P < .0001), but there was no difference in total medical
costs ($48,669 vs $46,112; difference, $2557; 95%
CI, $8043 to $13,156; P ¼ .64). After discounting at 3% per
annum, total medical costs for early EVAR and surveillance
patients remained similar ($47,765 vs $43,532; difference,
4232; 95% CI, $5561 to $14,025; P ¼ .40). There were no
treatment-related differences in quality of life at 24 months.*Full articles available online at www.jvascsurg.org
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http://dx.doi.org/10.1016/S1078-5884(13)00438-3Conclusions: A treatment strategy involving early repair of
smaller AAA with EVAR is associated with no difference in
total medical costs at 48 months vs surveillance with serial
imaging studies. Longer follow-up is required to determine
whether the late medical cost increases observed for sur-
veillance will persist beyond 48 months.Early report from an investigator-initiated investigational
device exemption clinical trial on physician-modiﬁed
endovascular grafts
Benjamin Ware Starnes, Billi Tatum
Objective: To determine whether a physician-modiﬁed
endovascular graft (PMEG) is a safe and effective method
for treating patients with juxtarenal aortic aneurysms who
are deemed unsuitable for open repair.
Methods: A nonrandomized, prospective, consecutively
enrolling investigational device exemption clinical trial was
used. Data collected on patients treated with PMEG be-
tween April 2011 and August 2012 were analyzed. Subjects
were followed with computed tomography, visceral duplex,
and four-view X-ray at 30 days, 6 months, and 1 year. The
protocol was designed to include follow-up to 5 years. The
primary safety end point was the proportion of subjects
who experienced a major adverse event (MAE) within 30
days of the procedure. The primary efﬁcacy end point was
the proportion of subjects experiencing treatment success.
Results: During the 16-month study period, 28 patients
were consented and 26 underwent endovascular repair
using PMEGs. Anatomic, operative details, and length of
stay were recorded and included aneurysm diameter
(mean, 62.5 mm), proximal neck length (mean, 4.4 mm),
graft manufacture time (mean, 59.7 minutes), procedure
time (mean, 169 minutes), ﬂuoroscopy time (mean, 42.8
minutes), total contrast usage (mean, 63 mL), estimated
blood loss (mean, 221 mL), and length of hospital stay
(mean, 4.9 days). There were 63 fenestrations created for 48
renal arteries and 15 superior mesenteric arteries. Renal
artery fenestrations were stented whenever possible (96%)
and superior mesenteric artery fenestrations were all left
unstented. There were no unanticipated adverse device
events, no MAEs, and only a single minor adverse device
event treated with a successful reintervention. At 30 days,
there were no type I or III endoleaks and only four type II
endoleaks (15.4%). Two patients died during the study
period, one at day 23 from respiratory failure (in-hospital
and 30-day mortality ¼ 3.8%) and one at day 210 from
urosepsis and congestive heart failure. MAEs occurred in
11.5% of patients at 30 days. The primary efﬁcacy end point
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freedom from migration, rupture or conversion, type I or III
endoleaks, or sac enlargement ¼ 100%, 100%, 87.5%, and
87.5%, respectively).
Conclusions: These preliminary data suggest that endovas-
cular repair with PMEG is safe and effective for managing
patients with juxtarenal aortic aneurysms. Endovascular
repair with PMEG has acceptable early rates of morbidity,
mortality, and endoleak. This endovascular aortic strategy is
particularly appealing for those patients presenting with
symptomatic or ruptured aortic aneurysms until reliable off-
the-shelf solutions become widely available.Effect of chronic oral anticoagulation with warfarin on the
durability and outcomes of endovascular aortic aneurysm
repair
Marques S. Johnson, Jasmine Chiang, Jens Eldrup-Jorgen-
sen, David E. Clark, Christopher T. Healey
Objective: Endoleak after endovascular aortic aneurysm
repair (EVAR) can affect the durability of the repair and lead
to continued sac expansion, rupture, and the need for
further endovascular or open surgical interventions. The
purpose of this study was to determine whether chronic
anticoagulation therapy with warfarin is associated with an
increased incidence of endoleak and thus increased need
for reintervention after EVAR.
Methods: We reviewed the records of 401 consecutive
patients who underwent EVAR at a single institution from
2003 until 2011. Patients on warfarin were compared with
a control group not on warfarin. Primary endpoints included
reintervention, deﬁned as rupture, explant, or angiography;
death from any cause; and a composite outcome of rein-
tervention or death. The presence of an endoleak at last
follow-up, identiﬁed by computed tomography or ultra-
sound scan, and increase of more than 5 mm in aneurysm
sac size were secondary endpoints. Cox proportional haz-
ards models were used to estimate the effect of warfarin
use on the primary and secondary outcomes, controlling for
age, gender, obesity, speciﬁc comorbidities, antiplatelet
drugs, statin use, and urgency of EVAR.
Results: Three hundred sixty-three patients with a median
follow-up period of 29 months had sufﬁcient data for
analysis. Warfarin use was not associated with an increased
risk of any of the primary endpoints. Controlling for cova-
riates and length of observation via proportional hazards
models, the effect of warfarin remained insigniﬁcant. It was
found, however, on regression analysis, that adverse out-
comes were more prevalent after emergency EVAR and in
patients deemed unﬁt for open surgical repair.
Conclusion: Chronic oral anticoagulation does not appear to
affect the incidence of endoleak after EVAR, nor does it
impact the need for reintervention or degree of sac
regression. We feel that warfarin may be safely used in
post-EVAR patients. It appears that adverse long-term out-
comes are more likely after emergency EVAR and in patients
deemed unﬁt for open surgery.A comparison between contrast-enhanced ultrasound
imaging and multislice computed tomography in detecting
and classifying endoleaks in the follow-up after
endovascular aneurysm repair
Verena M. Gürtler, Wieland H. Sommer, Georgios Meimar-
akis, Reinhard Kopp, Rolf Weidenhagen, Maximilian F.
Reiser, Dirk-André Clevert
Background: This study compared contrast-enhanced ul-
trasound (CEUS) imaging and multislice computed tomog-
raphy (MS-CT) angiography in detecting and classifying
endoleaks in the follow-up of patients after endovascular
aneurysm repair (EVAR).
Methods: This retrospective study consisted of 171 patients
with CEUS imaging and MS-CT angiography follow-up ex-
aminations after EVAR. During follow-up, 489 CEUS and 421
MS-CT examinations were assessed. B-scan, color Doppler,
and CEUS imaging were performed in all patients. MS-CT
was performed with a 16-slice up to 128-slice scanner.
Results: From the 132 patients in our cohort, we obtained
200 contemporary imaging examination pairs. MS-CT was
used as the preferred examination in determining the
presence of an endoleak. The true-positive rate for the
detection of endoleaks with CEUS imaging was 42% (84 of
200), the false-positive rate was 4% (8 of 200), the true-
negative rate was 52% (105 of 200), and the false-negative
rate was 2% (3 of 200). The sensitivity of CEUS imaging was
therefore 97%, and the speciﬁcity was 93%. The McNemar
test value was 0.227, and the k coefﬁcient was 0.889.
Conclusions: CEUS imaging appears to be as good as MS-
CT angiography in the detection of endoleaks in the follow-
up after EVAR, with the added advantages of no radiation
dose and no nephrotoxicity of the contrast agents. A switch
of the preferred examination from MS-CT to CEUS imaging
should be considered.Transplantation of puriﬁed CD34D cells in the treatment
of critical limb ischemia
Zhihui Dong, Bin Chen, Weiguo Fu, Yuqi Wang, Daqiao Guo,
Zheng Wei, Xin Xu, Farrell Owen Mendelsohn
Background: This study investigated the feasibility, safety,
and efﬁcacy of the intramuscular injection of CD34þ cells
isolated from peripheral blood mononuclear cells (PB-
MNCs) mobilized by granulocyte colony-stimulating factor
(G-CSF) for the management of patients with critical limb
ischemia (CLI) who were considered unlikely to have suc-
cessful long-term revascularization with open bypass or
endovascular methods. Cell therapy represents a new
treatment modality for this subgroup of patients with CLI.
To date, bone marrow or PB-MNCs have usually been used
for transplantation. The current pilot study investigated
whether the transplantation of puriﬁed CD34þ cells only
would be competent in ischemia relief and limb salvage.
Methods: From May 2009 to July 2011, 25 patients (mean
age, 44  12 years) were enrolled, and 25 lower extremities
and three upper extremities were treated. After subcu-
taneous administration of G-CSF for 5 days at a dose of 5 to
266 European Journal of Vascular and Endovascular Surgery Volume 46 Issue 2 August/201310 mg/kg, apheresis and immunomagnetic separation were
performed to acquire the isolated CD34þ cells, which were
then intramuscularly injected into the ischemic sites. The
patients were divided into three groups: low-dose, 105/kg;
medium-dose, 5  105/kg; and high-dose, 106/kg. The
overall outcomes among all patients and the comparison
among the groups were evaluated.
Results: During the follow-up of 6 to 33 months, the overall
outcomes showed that the Wong-Baker FACES pain rating
scale score (WFPRSS) decreased from 7  2 to 3  3 (P <
.001) and 1  2 (P < .001) at 1 and 2 months, respectively;
at 3 and 6 months, respectively, the peak pain-free walking
time increased from 4  3 to 13  7 (P < .001) and 18  6
minutes (P < .001), the ankle-brachial index increased from
0.46  0.21 to 0.60  0.17 (P ¼ .003) and 0.67  0.15 (P ¼
.001), and the transcutaneous partial oxygen pressure
increased from 27  10 to 41  11 (P < .001) and 55  12
mm Hg (P < .001). Ulcers were healed in 10 of the 14 pa-
tients; four patients required above-knee or below-knee
amputation  3 months. The Kaplan-Meier estimate of the
rate of freedom from major amputation at 6 months was
84% (95% conﬁdence interval, 63%-94%). The comparison
among the three groups (low-dose, 5; medium-dose, 11;
high-dose, 9) revealed no signiﬁcant difference, except that
the WFPRSS improvement at 1 month from baseline in the
high-dose group (6.3  1.7) was signiﬁcantly superior to
that in the low-dose (3.2  3.3; P ¼ .0487) and medium-
dose (3.7  2.8; P ¼ .0352) groups.
Conclusions: Transplantation of CD34þ cells isolated from
G-CSF-mobilized PB-MNCs appears to be feasible and safe,
showing encouraging outcomes in the treatment of CLI
patients who appear to have compromised options for long-
term revascularization.Accuracy of administrative data versus clinical data to
evaluate carotid endarterectomy and carotid stenting
Rodney P. Bensley, Shunsuke Yoshida, Ruby C. Lo, Margriet
Fokkema, Allen D. Hamdan, Mark C. Wyers, Elliot L. Chaikof,
Marc L. Schermerhorn
Objective: Administrative data have been used to compare
carotid endarterectomy (CEA) and carotid artery stenting
(CAS). However, there are limitations in deﬁning symptom
status, Centers for Medicare and Medicaid Services high-risk
status, as well as complications. Therefore, we did a direct
comparison between administrative data and physician
chart review as well as between data collected for the
National Surgical Quality Improvement Program (NSQIP)
and physician chart review for CEA and CAS.
Methods: We performed an outcomes analysis on all CEA
and CAS procedures from 2005 to 2011. We obtained In-
ternational Classiﬁcation of Diseases, Ninth Revision diag-
nosis codes from hospital discharge records regarding
symptom status, high-risk status, and perioperative stroke.
We also obtained data on all CEA patients submitted to
NSQIP over the same time period. One of the study authors
(R.B.) then performed a chart review of the same patientsto determine symptom status, high-risk status, and peri-
operative strokes and the results were compared.
Results:We identiﬁed 1342 patients who underwent CEA or
CAS between 2005 and 2011 and 392 patients who un-
derwent CEA that were submitted to NSQIP. Administrative
data identiﬁed fewer symptomatic patients (17.0% vs
34.0%), physiologic high-risk patients (9.3% vs 23.0%), and
anatomic high-risk patients (0% vs 15.2%). Although
administrative data identiﬁed a similar proportion of peri-
operative strokes (1.9% vs 2.0%), this was due to the fact
that these data identiﬁed eight false positive and nine false
negative perioperative strokes. NSQIP data identiﬁed more
symptomatic patients compared with chart review (44.1%
vs 30.3%), fewer physiologic high-risk patients (13.0% vs
18.6%), fewer anatomic high-risk patients (0% vs 6.6%), and
a similar proportion of perioperative strokes (1.5% vs 1.8%,
only one false negative stroke and no false positives).
Conclusions: Administrative data are unreliable for deter-
mining symptom status, high-risk status, and perioperative
stroke and should not be used to analyze CEA and CAS.
NSQIP data do not adequately identify high-risk patients,
but do accurately identify perioperative strokes and to
a lesser degree, symptom status.Randomized clinical trial comparing endovenous laser
ablation and stripping of the great saphenous vein with
clinical and duplex outcome after 5 years
Lars Rasmussen, Martin Lawaetz, Lars Bjoern, Allan Blem-
ings, Bo Eklof
Objective: This is the ﬁrst randomized controlled trial with
a 5-year follow-up comparing endovenous laser ablation
(EVLA) with high ligation and pin-stripping in patients with
great saphenous vein (GSV) incompetence.
Methods: One hundred twenty-one consecutive patients
(137 legs) with GSV incompetence were randomized to
EVLA (980 nm bare ﬁber) or high ligation and stripping using
tumescent local anesthesia with light sedation. Mini-phle-
bectomies were performed in all patients. The patients
were examined with duplex scanning before treatment and
after 12 days, and then after 1, 3, and 6 months, and yearly
thereafter for up to 5 years. The primary end point was
open reﬂuxing GSV. Secondary end points were recurrent
varicose veins, frequency of reoperations, Venous Clinical
Severity Score, and quality of life scores (Aberdeen Varicose
Vein Symptoms Severity Score and Short Form-36).
Results: In the EVLA and stripping group, nine (Kaplan-
Meier [KM] estimate, 17.9%) and four (KM estimate, 10.1%)
of GSVs had open reﬂuxing segments of 5 cm or more (ns).
Clinical recurrence was recorded in 24 (KM estimate, 46.6%)
and 25 (KM estimate, 54.6%), whereas reoperations were
performed in 17 (KM estimate, 38.6%) and 15 (KM estimate,
37.7%) legs (ns). Venous Clinical Severity Score and Aber-
deen Varicose Vein Symptoms Severity Score improved
whereas Medical Outcomes Study Short Form-36 quality of
life score improved in several domains in both groups with
no difference between the groups.
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trolled trial comparing EVLA with open surgery in patients
with GSV incompetence did not show any signiﬁcant dif-
ference between the two groups in primary or secondary
end points, perhaps because of the small sample size. EVLA
seems to be a valid alternative to open surgery.Factors impacting follow-up care after placement of
temporary inferior vena cava ﬁlters
Elsie Gyang, Mohamed Zayed, E. John Harris, Jason T. Lee,
Ronald L. Dalman, Matthew W. Mell
Objective: Rates of inferior vena cava (IVC) ﬁlter retrieval
have remained suboptimal, in part because of poor follow-
up. The goal of our study was to determine demographic
and clinical factors predictive of IVC ﬁlter follow-up care in
a university hospital setting.
Methods: We reviewed 250 consecutive patients who
received an IVC ﬁlter placement with the intention of sub-
sequent retrieval between March 2009 and October 2010.
Patient demographics, clinical factors, and physician specialty
were evaluated. Multivariate logistic regression analysis was
performed to identify variables predicting follow-up care.Results: In our cohort, 60.7% of patients received follow-up
care; of those, 93% had IVC ﬁlter retrieval. Major indications
for IVC ﬁlter placement were prophylaxis for high risk sur-
gery (53%) and venous thromboembolic event with con-
traindication and/or failure of anticoagulation (39%).
Follow-up care was less likely for patients discharged to
acute rehabilitation or skilled nursing facilities (P < .0001),
those with central nervous system pathology (eg, cerebral
hemorrhage or spinal fracture; P < .0001), and for those
who did not receive an IVC ﬁlter placement by a vascular
surgeon (P < .0001). In a multivariate analysis, discharge
home (odds ratio [OR], 4.0; 95% conﬁdence interval [CI],
1.99-8.2; P < .0001), central nervous system pathology (OR,
0.46; 95% CI, 0.22-0.95; P ¼ .04), and IVC ﬁlter placement
by the vascular surgery service (OR, 4.7; 95% CI, 2.3-9.6; P<
.0001) remained independent predictors of follow-up care.
Trauma status and distance of residence did not signiﬁcantly
impact likelihood of patient follow-up.
Conclusions: Service-dependent practice paradigms play
a critical role in patient follow-up and IVC ﬁlter retrieval
rates. Nevertheless, speciﬁc patient populations are more
prone to having poorer rates of follow-up. Such trends
should be factored into institutional quality control goals
and patient-centered care.
